Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)
Year: 2015
Type: article
Source: Blood
Authors: Jeffrey A Zonder, Saad Usmani, Emma C. Scott, Craig C. Hofmeister, Nikoletta Lendvai, Jesus G. Berdeja, Larry D. Anderson, Parameswaran Hari, Seema Singhal, Gregory Orloff, Michael Craig, Jason Valent, Wes Lee, Lowell Hart, J Hrom, Stephano Tarantolo, Edward Faber, Gary J Schiller, Jennifer Schreiber, Colleen Oliver, Selena A Rush, Brian Tunquist, Mieke Ptaszynski, Noopur S. Raje
Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, Carolinas Healthcare System, Levine Cancer Institute, Oregon Health & Science University, OHSU Knight Cancer Institute, The Ohio State University, Memorial Sloan Kettering Cancer Center, Sarah Cannon, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Medical College of Wisconsin, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, West Virginia University Hospitals, Cleveland Clinic, Florida Cancer Specialists & Research Institute, Forrest General Hospital, Nebraska Cancer Specialists, Oncology Hematology Care, University of California, Los Angeles, Los Angeles Medical Center, Array BioPharma (United States), Massachusetts General Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2562450445